The ACE insertion/deletion polymorphism and risk of cancer, a review and meta-analysis of the literature

Current Cancer Drug Targets

Volumn 11, Issue 4, 2011, Pages 421-430

  Ruiter, R ^a,b   Visser, L E ^a   van Duijn, C M ^a   Stricker, B H Ch ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Drug Safety Unit   (Netherlands)

Author keywords

ACE; Cancer; Polymorphism; Renin angiotensin system

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

CANCER RISK; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; NEOPLASM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 79955607344     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911795538147     Document Type: Review

References (69)

1. Erdos, E. G.; Skidgel, R. A. The angiotensin I-converting enzyme. Lab. Invest. 1987, 56, 345-348.
2. Reilly, C. F.; Tewksbury, D. A.; Schechter, N. M.; Travis, J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J. Biol. Chem. 1982, 257, 8619-8622.
3. Ager, E. I.; Neo, J.; Christophi, C. The renin-angiotensin system and malignancy. Carcinogenesis 2008, 29, 1675-1684.
4. Deshayes, F.; Nahmias, C. Angiotensin receptors: A new role in cancer? Trends Endocrinol. Metab. 2005, 16, 293-299.
5. Ino, K.; Shibata, K.; Kajiyama, H.; Nawa, A.; Nomura, S.; Kikkawa, F. Manipulating the angiotensin system--new approaches to the treatment of solid tumours. Expert Opin. Biol. Ther. 2006, 6, 243-255.
6. Khakoo, A. Y.; Sidman, R. L.; Pasqualini, R.; Arap, W. Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res. 2008, 68, 9112-9115.
7. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to virchow? Lancet 2001, 357, 539-545.
8. 2 receptors. J. Inflamm. (Lond.) 2004, 1, 3.
9. Smith, G. R.; Missailidis, S. Learning from cancer: The adaptive growth, wound and immune responses. Gene Ther. Mol. Biol. 2009, 13, 158-185.
10. De Paepe, B.; Verstraeten, V. L.; De Potter, C. R.; Vakaet, L. A.; Bullock, G. R. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem. Cell Biol. 2001, 116, 247-254.
11. Fujimoto, Y.; Sasaki, T.; Tsuchida, A.; Chayama, K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001, 495, 197-200.
12. Kikkawa, F.; Mizuno, M.; Shibata, K.; Kajiyama, H.; Morita, T.; Ino, K.; Nomura, S.; Mizutani, S. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am. J. Obstet. Gynecol. 2004, 190, 1258-1263.
13. Suganuma, T.; Ino, K.; Shibata, K.; Kajiyama, H.; Nagasaka, T.; Mizutani, S.; Kikkawa, F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 2005, 11, 2686-2694.
14. Takeda, H.; Kondo, S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am. J. Pathol. 2001, 158, 1633-1637.
15. Uemura, H.; Ishiguro, H.; Nakaigawa, N.; Nagashima, Y.; Miyoshi, Y.; Fujinami, K.; Sakaguchi, A.; Kubota, Y. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther. 2003, 2, 1139-1147.
16. 2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br. J. Cancer 2008, 99, 160-166.
17. Ino, K.; Shibata, K.; Kajiyama, H.; Yamamoto, E.; Nagasaka, T.; Nawa, A.; Nomura, S.; Kikkawa, F. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br. J. Cancer 2006, 94, 552-560.
18. Rocken, C.; Rohl, F. W.; Diebler, E.; Lendeckel, U.; Pross, M.; Carl-McGrath, S.; Ebert, M. P. The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1206-1212.
19. Lever, A. F.; Hole, D. J.; Gillis, C. R.; McCallum, I. R.; McInnes, G. T.; MacKinnon, P. L.; Meredith, P. A.; Murray, L. S.; Reid, J. L.; Robertson, J. W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352, 179-184.
20. Friis, S.; Sorensen, H. T.; Mellemkjaer, L.; McLaughlin, J. K.; Nielsen, G. L.; Blot, W. J.; Olsen, J. H. Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in denmark. Cancer 2001, 92, 2462-2470.
21. Fryzek, J. P.; Poulsen, A. H.; Lipworth, L.; Pedersen, L.; Norgaard, M.; McLaughlin, J. K.; Friis, S. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res. Treat 2006, 97, 231-236.
22. Gonzalez-Perez, A.; Ronquist, G.; Garcia Rodriguez, L. A. Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol. Drug Saf. 2004, 13, 581-585.
23. Grossman, E.; Messerli, F. H.; Goldbourt, U. Antihypertensive therapy and the risk of malignancies. Eur. Heart J. 2001, 22, 1343-1352.
24. Kosaka, T.; Miyajima, A.; Takayama, E.; Kikuchi, E.; Nakashima, J.; Ohigashi, T.; Asano, T.; Sakamoto, M.; Okita, H.; Murai, M.; Hayakawa, M. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007, 67, 41-49.
25. Li, C. I.; Malone, K. E.; Weiss, N. S.; Boudreau, D. M.; Cushing-Haugen, K. L.; Daling, J. R. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003, 98, 1504-1513.
26. Lindholm, L. H.; Anderson, H.; Ekbom, T.; Hansson, L.; Lanke, J.; Dahlof, B.; de Faire, U.; Forsen, K.; Hedner, T.; Linjer, E.; Schersten, B.; Wester, P.; Moller, T. Relation between drug treatment and cancer in hypertensives in the Swedish trial in old patients with hypertension 2: A 5-year, prospective, randomised, controlled trial. Lancet 2001, 358, 539-544.
27. Meier, C. R.; Derby, L. E.; Jick, S. S.; Jick, H. Angiotensinconverting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch. Intern. Med. 2000, 160, 349-353.
28. Ronquist, G.; Rodriguez, L. A.; Ruigomez, A.; Johansson, S.; Wallander, M. A.; Frithz, G.; Svardsudd, K. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004, 58, 50-56.
29. Stahl, M.; Bulpitt, C. J.; Palmer, A. J.; Beevers, D. G.; Coles, E. C.; Webster, J. Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: A report from the department of health hypertension care computing project (DHCCP). J. Hum. Hypertens. 2000, 14, 299-304.
30. Wilop, S.; von Hobe, S.; Crysandt, M.; Esser, A.; Osieka, R.; Jost, E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 2009, 135, 1429-1435.
31. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Fukui, H. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr. Cancer Drug Targets 2004, 4, 555-567.
32. Lindberg, H.; Nielsen, D.; Jensen, B.V.; Eriksen, J.; Skovsgaard, T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta. Oncol. 2004, 43, 142-152.
33. Rigat, B.; Hubert, C.; Alhenc-Gelas, F.; Cambien, F.; Corvol, P.; Soubrier, F. An insertion/deletion polymorphism in the angiotensin i-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 1990, 86, 1343-1346.
34. Rigat, B.; Hubert, C.; Corvol, P.; Soubrier, F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic. Acids. Res. 1992, 20, 1433.
35. Castellon, R.; Hamdi, H. K. Demystifying the ace polymorphism: From genetics to biology. Curr. Pharm. Des. 2007, 13, 1191-1198.
36. Tiret, L.; Rigat, B.; Visvikis, S.; Breda, C.; Corvol, P.; Cambien, F.; Soubrier, F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ace levels. Am. J. Hum. Genet. 1992, 51, 197-205.
37. Lee, E. J. Population genetics of the angiotensin-converting enzyme in Chinese. Br. J. Clin. Pharmacol. 1994, 37, 212-214.
38. van der Knaap, R.; Siemes, C.; Coebergh, J. W.; van Duijn, C. M.; Hofman, A.; Stricker, B. H. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The Rotterdam Study. Cancer 2008, 112, 748-757.
39. Vairaktaris, E.; Yapijakis, C.; Tsigris, C.; Vassiliou, S.; Derka, S.; Nkenke, E.; Spyridonidou, S.; Vylliotis, A.; Vorris, E.; Ragos, V.; Neukam, F. W.; Patsouris, E. Association of angiotensinconverting enzyme gene insertion/deletion polymorphism with increased risk for oral cancer. Acta. Oncol. 2007, 46, 1097-1102.
40. Goto, Y.; Ando, T.; Nishio, K.; Ishida, Y.; Kawai, S.; Goto, H.; Hamajima, N. The ace gene polymorphism is associated with the incidence of gastric cancer among h. Pylori seropositive subjects with atrophic gastritis. Asian Pac. J. Cancer Prev. 2005, 6, 464-467.
41. Goto, Y.; Ando, T.; Nishio, K.; Ishida, Y.; Kawai, S.; Goto, H.; Hamajima, N. The ace gene polymorphism is associated with the incidence of gastric cancer among h. Pylori seropositive subjects with atrophic gastritis. Asian Pac. J. Cancer Prev. 2006, 7, 502.
42. Ebert, M. P.; Lendeckel, U.; Westphal, S.; Dierkes, J.; Glas, J.; Folwaczny, C.; Roessner, A.; Stolte, M.; Malfertheiner, P.; Rocken, C. The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 2987-2989.
43. Rocken, C.; Lendeckel, U.; Dierkes, J.; Westphal, S.; Carl-McGrath, S.; Peters, B.; Kruger, S.; Malfertheiner, P.; Roessner, A.; Ebert, M. P. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin. Cancer Res. 2005, 11, 2526-2530.
44. Sugimoto, M.; Furuta, T.; Shirai, N.; Ikuma, M.; Sugimura, H.; Hishida, A. Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in japan. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1929-1934.
45. Urata, H.; Kinoshita, A.; Misono, K. S.; Bumpus, F. M.; Husain, A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 1990, 265, 22348-22357.
46. Rocken, C.; Neumann, K.; Carl-McGrath, S.; Lage, H.; Ebert, M. P.; Dierkes, J.; Jacobi, C. A.; Kalmuk, S.; Neuhaus, P.; Neumann, U. The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. Neoplasia 2007, 9, 716-722.
47. Nikiteas, N.; Tsigris, C.; Chatzitheofylaktou, A.; Yannopoulos, A. No association with risk for colorectal cancer of the insertion/deletion polymorphism which affects levels of angiotensin-converting enzyme. In Vivo 2007, 21, 1065-1068.
48. Toma, M.; Cimponeriu, D.; Apostol, P.; Stavarachi, M.; Cojocaru, M.; Belusica, L.; Craciun, A. M.; Radu, I.; Gavrila, L. Lack of association between ACE ID polymorphism and colorectal cancer in Romanian patients. Chirurgia (Bucur) 2009, 104, 553-556.
49. Srivastava, K.; Srivastava, A.; Mittal, B. Angiotensin I-converting enzyme insertion/deletion polymorphism and increased risk of gall bladder cancer in women. DNA Cell Biol. 2010, 29, 417-422.
50. Koh, W. P.; Yuan, J. M.; Sun, C. L.; van den Berg, D.; Seow, A.; Lee, H. P.; Yu, M. C. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003, 63, 573-578.
51. Haiman, C. A.; Henderson, S. O.; Bretsky, P.; Kolonel, L. N.; Henderson, B. E. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: The multiethnic cohort. Cancer Res. 2003, 63, 6984-6987.
52. Gonzalez-Zuloeta Ladd, A. M.; Arias Vasquez, A.; Sayed-Tabatabaei, F. A.; Coebergh, J. W.; Hofman, A.; Njajou, O.; Stricker, B.; van Duijn, C. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 2143-2146.
53. Yaren, A.; Turgut, S.; Kursunluoglu, R.; Oztop, I.; Turgut, G.; Kelten, C.; Erdem, E. Association between the polymorphism of the angiotensin-converting enzyme gene and tumor size of breast cancer in premenopausal patients. Tohoku J. Exp. Med. 2006, 210, 109-116.
54. Yaren, A.; Turgut, S.; Kursunluoglu, R.; Oztop, I.; Turgut, G.; Degirmencioglu, S.; Kelten, C.; Erdem, E. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with breast cancer and effects on prognostic factors. J. Investig. Med. 2007, 55, 255-261.
55. Alves Correa, S. A.; Ribeiro de Noronha, S. M.; Nogueira-de-Souza, N. C.; Valleta de Carvalho, C.; Massad Costa, A. M.; Juvenal Linhares, J.; Vieira Gomes, M. T.; Guerreiro da Silva, I. D. Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. J. Renin Angiotensin Aldosterone Syst. 2009, 10, 51-58.
56. Usmani, B. A.; Janeczko, M.; Shen, R.; Mazumdar, M.; Papandreou, C. N.; Nanus, D. M. Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer. Br. J. Cancer 2000, 82, 550-552.
57. Yigit, B.; Bozkurt, N.; Narter, F.; Yilmaz, H.; Yucebas, E.; Isbir, T. Genetic polymorphism of angiotensin i-converting enzyme (ACEI) and prostate cancer risk. Advances in Molecular Medicine 2006, 2, 65-68.
58. Yigit, B.; Bozkurt, N.; Narter, F.; Yilmaz, H.; Yucebas, E.; Isbir, T. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis. Anticancer Res. 2007, 27, 933-936.
59. Sierra Diaz, E.; Sanchez Corona, J.; Rosales Gomez, R. C.; Gutierrez Rubio, S. A.; Vazquez Camacho, J. G.; Solano Moreno, H.; Moran Moguel, M. C. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. J. Renin Angiotensin Aldosterone Syst. 2009, 10, 241-246.
60. Freitas-Silva, M.; Pereira, D.; Coelho, C.; Bicho, M.; Lopes, C.; Medeiros, R. Angiotensin i-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women. Cancer Genet. Cytogenet. 2004, 155, 42-46.
61. Cheon, K. T.; Choi, K. H.; Lee, H. B.; Park, S. K.; Rhee, Y. K.; Lee, Y. C. Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 2000, 178, 351-360.
62. Yaren, A.; Oztop, I.; Turgut, S.; Turgut, G.; Degirmencioglu, S.; Demirpence, M. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp. Biol. Med. (Maywood) 2008, 233, 32-37.
63. Nacak, M.; Nacak, I.; Sanli, M.; Ozkur, M.; Pektas, M.; Aynacioglu, A. S. Association of angiotensin converting enzyme gene insertion/deletion polymorphism with lung cancer in Turkey. Cancer Genet. Cytogenet. 2010, 198, 22-26.
64. Rothman, K. J. Modern Epidemiology. Lippincott Williams & Wilkins; 2008.
65. Uemura, H.; Hasumi, H.; Kawahara, T.; Sugiura, S.; Miyoshi, Y.; Nakaigawa, N.; Teranishi, J.; Noguchi, K.; Ishiguro, H.; Kubota, Y. Pilot study of angiotensin II receptor blocker in advanced hormonerefractory prostate cancer. Int. J. Clin. Oncol. 2005, 10, 405-410.
66. 2 receptor stimulation may halt progression of pheochromocytoma. Ann. N. Y. Acad. Sci. 2006, 1073, 436-443.
67. Sayed-Tabatabaei, F. A.; Schut, A. F.; Hofman, A.; Bertoli-Avella, A. M.; Vergeer, J.; Witteman, J. C.; van Duijn, C. M. A study of gene-environment interaction on the gene for angiotensin converting enzyme: A combined functional and population based approach. J. Med. Genet. 2004, 41, 99-103.
68. Wu, J.; Akaike, T.; Maeda, H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 1998, 58, 159-165.
69. Fischer, M.; Baessler, A.; Schunkert, H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc. Res. 2002, 53, 672-677.